Get the Stockscreener App
2.44
20.26%
-0.62
Orchestra Biomed Holdings Inc stock is traded at $2.44, with a volume of 1.72M.
It is down -20.26% in the last 24 hours and down -11.91% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$3.06
Open:
$2.7
24h Volume:
1.72M
Relative Volume:
6.08
Market Cap:
$93.48M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-1.6267
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
-25.84%
1M Performance:
-11.91%
6M Performance:
-53.44%
1Y Performance:
-64.38%
1-Day Range:
$2.44
$2.75
1-Week Range:
$2.44
$3.53
52-Week Range:
$2.37
$7.24
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.44 | 117.24M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
How to integrate Orchestra BioMed Holdings Inc. into portfolio analysis toolsOversold Stock Bounce Playbook Generator - Newser
Will Orchestra BioMed Holdings Inc. benefit from macro trendsSummary of Reliable Long-Term Trade Models - Newser
Is Orchestra BioMed Holdings Inc. still worth holding after the dipEntry Zone Watchlist With Momentum Focus - Newser
Can Orchestra BioMed Holdings Inc. hit a new high this monthFree Risk Adjusted Technical Entry Plan - Newser
Applying Wyckoff theory to Orchestra BioMed Holdings Inc. stockFree Investment Playbook for Growing Markets - Newser
Latham Advises on Orchestra BioMed’s US$40 Million Public Offering - Latham & Watkins LLP
Trendlines Suggest Orchestra BioMed Holdings Inc. May Bottom Out Soon - metal.it
Orchestra BioMed Holdings prices public offering of 9.4 million shares at $2.75. - AInvest
Orchestra BioMed Announces Pricing of $40 Million Public Offering - GlobeNewswire
New Product Launches: Will They Boost Orchestra BioMed Holdings Inc. Stock in 2025 - Newser
Why Orchestra BioMed Holdings Inc. is moving todayFree Short Term Buy Zone Stock Alerts - Newser
Real time pattern detection on Orchestra BioMed Holdings Inc. stockFree Fast Return Equity Trade Forecast - Newser
When is Orchestra BioMed Holdings Inc. stock expected to show significant growthFree Stock Insights For Every Investor - jammulinksnews.com
What MACD and RSI say about Orchestra BioMed Holdings Inc.Free Day Trading Signals With High Precision - Newser
Can momentum traders help lift Orchestra BioMed Holdings Inc.Sector-Wise Equity Performance Trend Forecast - Newser
Can trapped investors hope for a rebound in Orchestra BioMed Holdings Inc.Daily Equity Signal Strength Summary Report - Newser
Can a trend reversal in Orchestra BioMed Holdings Inc. lead to recoveryHigh Yield Watchlist with Filtered Picks - Newser
Real time scanner hits for Orchestra BioMed Holdings Inc. explainedSector-Wise Equity Performance Trend Forecast - Newser
Published on: 2025-07-31 20:31:14 - Newser
Orchestra BioMed secures $70 million from Ligand and Medtronic By Investing.com - Investing.com UK
How strong is Orchestra BioMed Holdings Inc. company’s balance sheetChart Pattern Growth Plan For Smart Trading - jammulinksnews.com
Orchestra BioMed announces public offering of common stock By Investing.com - Investing.com Nigeria
Orchestra BioMed announces public offering of common stock - Investing.com Australia
Orchestra BioMed Announces Proposed Public Offering - The Manila Times
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire
Orchestra BioMed Announces Strategic Public Offering: Funding Next-Gen Cardiac and Vascular Therapies - Stock Titan
$70M Strategic Investment Powers Orchestra BioMed's Revolutionary Leadless Pacemaker Technology - Stock Titan
What are analysts’ price targets for Orchestra BioMed Holdings Inc. in the next 12 monthsAI Powered Planner Backed By Experts - jammulinksnews.com
Is Orchestra BioMed Holdings Inc. a candidate for recovery playFuture Growth Stock Forecasting Strategy - Newser
Signal strength of Orchestra BioMed Holdings Inc. stock in tech scannersReal-Time Investment Signal Forecast with AI - Newser
Drawdown in Orchestra BioMed Holdings Inc. May Be Nearing EndProfit Focused Stock Screener Results Released - metal.it
Published on: 2025-07-30 05:14:14 - Newser
Using fundamentals and technicals on Orchestra BioMed Holdings Inc.High Return Trade Roadmap with Setup Filters - Newser
Why Orchestra BioMed Holdings Inc. stock attracts strong analyst attentionWatchlist for Low Risk High Return Stocks Updated - metal.it
Regression analysis insights on Orchestra BioMed Holdings Inc. performanceFree Daily Growth Stock Pick Reports - Newser
Orchestra BioMed Holdings Inc. Stock Fails to Break Resistance Traders ReactHigh Conviction Intraday Stock Signals Detected - metal.it
How Interest Rate Changes Impact Orchestra BioMed Holdings Inc. Stock PerformanceFree Swing Trading Plan With Smart Signals - Newser
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):